CN102242212A - HCM (Hypertrophic Cardiomyopathy) genotyping method and kit - Google Patents
HCM (Hypertrophic Cardiomyopathy) genotyping method and kit Download PDFInfo
- Publication number
- CN102242212A CN102242212A CN2011101927459A CN201110192745A CN102242212A CN 102242212 A CN102242212 A CN 102242212A CN 2011101927459 A CN2011101927459 A CN 2011101927459A CN 201110192745 A CN201110192745 A CN 201110192745A CN 102242212 A CN102242212 A CN 102242212A
- Authority
- CN
- China
- Prior art keywords
- gene
- pcr
- hypertrophic cardiomyopathy
- seq
- tnnt2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a technical scheme to provide an HCM (Hypertrophic Cardiomyopathy) genotyping method and a kit. The method comprises the following steps of: a, carrying out a gene mutation test on genes MYH7 (Myosin Heavy Chain 7), MYBPC3 (Myosin Binding Protein C 3) and TNNT2 (Troponin 2) in a sample DNA (Deoxyribonucleic Acid), wherein the gene mutation test comprises PCR (Polymerase Chain Reaction) amplification sequencing of MYH7, MYBPC3 and TNNT2 gene exons; and b, comparing sequences obtained by amplification in the step a with a standard sequence of a database to determine a genotyping result. The invention has the beneficial effects of: (1) assisting the early diagnosis: finding out asymptomatic generation sufferers and non-generation sufferers in family members; and (2) assisting to guide the selective birth so as to eliminate the spread of the HCM in the family.
Description
Technical field
The present invention relates to the gene type field, specifically belong to a kind of hypertrophic cardiomyopathy methods of genotyping and detection kit thereof.
Background technology
Hypertrophic cardiomyopathy (HCM) is one of modal myocardosis, is feature with left ventricle and right ventricle and interventricular septum asymmetry plumpness, gets rid of other cardiovascular disorder that may cause myocardial hypertrophy and general diseases.Its clinical manifestation is various, from asymptomatic to slight uncomfortable in chest, palpitaition again to malignant arrhythmia, heart failure, even adolescence sudden death etc.
According to estimates, the HCM sickness rate is about 1/500 in the general population.Along with finishing of the molecular biological fast development and the Human Genome Project, myocardiac Disease-causing gene research has obtained remarkable progress.Confirmed that hypertrophic cardiomyopathy is an autosome dominant disease, the single allele sudden change can be caused a disease.This disease has 55% morbidity to be familial aggregation approximately, is called familial hypertrophic cardiomyopathy (FHCM).Up to now, determined 11 coding muscle segment protein genes 200 surplus the kind sudden change, can cause simple property HCM, outside other hearts performances and heart, show.Gene comprising 5 coding thick filaments: β-myoglobulin heavy chain gene (MYH7), cardiac myosin binding protein-C gene (MYBPC3).α-myoglobulin heavy chain gene (MYH6), essential light chain gene (MYL3), regulation and control light chain gene (MYL3); The gene of 5 coding thin filaments: serum cardiac troponin T gene (TNNI3), actin gene (ACTC), TnT gene (TNNI2), cardiac troponin C gene (TNNC1) and α-tropomyosin gene (TPM1); 1 coding crin connects egg from gene: TTN.Wherein, modal three kinds of mutation types are β-myoglobulin heavy chain gene (MYH7), cardiac myosin binding protein-C gene (MYBPC3) and cardiac troponin T gene (TNNT2), account for the 70-90% of familial hypertrophic cardiomyopathy.
Hypertrophic cardiomyopathy is because clinical manifestation is very various, and making a definite diagnosis at present mainly is by laboratory examination.Ultrasound cardiogram is still the most frequently used, the most reliable, the most most economical diagnostic method of hypertrophic cardiomyopathy diagnosis at present.Also have inspection methods such as heart nuclear-magnetism, ECG change in addition.But the patient that the methods for clinical diagnosis weak point is made a definite diagnosis is the middle and advanced stage that has developed into morbidity, and this all is a unfavorable factor concerning treatment and operation.
The Disease-causing gene of HCM and mutational site are very big at country variant, distributional difference between not agnate.And the HCM myocardosis has become the great public health problem that influences China resident physical and mental health and population life quality, in view of increasing myocardosis relevant with inherited genetic factors, more and more be necessary for myocardiac gene type, and still blank at present in this respect both at home and abroad.
Summary of the invention
The technical problem that the present invention mainly solves is the detection of carrying out transgenation by Disease-causing gene MYH7, MYBPC3 and TNNT2 to HCM, comes assistant identification whether to carry the sudden change of HCM myocardosis Disease-causing gene from gene order and molecular structure level.
Technical scheme provided by the invention is for providing a kind of hypertrophic cardiomyopathy methods of genotyping, and described method comprises:
A, gene M YH7, MYBPC 3 and TNNT2 in the sample DNA are carried out the detection of transgenation, the detection of described transgenation comprises the pcr amplification and the dna sequencing of the gene extron of MYH7, MYBPC3 and TNNT2,
C, the sequence that obtains after the amplification order-checking among the step b is compared with the standard sequence in the database, thus definite gene type result.
Preferably, described pcr amplification and dna sequencing comprise PCR sequence amplification, PCR product purification and dideoxy chain termination dna sequencing.
Preferably, the reaction system of described PCR sequence amplification is 2 μ M primers, the 2mM dNTP mix of 1 μ L, the MgCl of 1 μ L15mM of 10 * PCR Buffer, the 1 μ L of 1 μ L
2, the Taq enzyme of 1U, the dna profiling of 1 μ L 20ng/ μ L, add distilled water to 10 μ L then,
Reaction conditions is: 94 ℃ of pre-sex change 5 minutes; 94 ℃ of sex change 30 seconds, 65 ℃ of annealing 30 seconds, 72 ℃ were extended totally 35 circulations 2 minutes; 72 ℃ were extended 5 minutes.
Preferably, the reaction system of described dideoxy chain termination dna sequencing is primer, the 1.875uL sterilization deionized water of 2.5 * BigDye, 0.875uL5 * BigDye Seq Buffer, the 1uL5pmoL/ μ L of 0.25uL, the PCR product of 1uL purifying;
Reaction conditions: 94 ℃ of pre-sex change 2 minutes; 94 ℃ of sex change 10 seconds, 55 ℃ of annealing 10 seconds, 60 ℃ were extended 25 circulations 3 minutes.
Preferably, described PCR product purification adopts the EDTA-Ethanol Method.
Preferably, the used universal sequencing primer thing sequence of described dideoxy chain termination dna sequencing is shown in SEQ ID NO:1-2.
Preferably, the pcr amplification primer base sequence of described MYH7 gene extron as: shown in the SEQ ID NO:3-28;
The pcr amplification primer base sequence of described MYBPC3 gene extron as: shown in the SEQ ID NO:29-50;
The pcr amplification primer base sequence of described TNNT2 gene extron as: shown in the SEQ ID NO:51-58.
Another technical scheme provided by the invention comprises the pcr amplification primer of the gene extron of MYH7, MYBPC3 and TNNT2 for a kind of hypertrophic cardiomyopathy gene PCR detection kit is provided,
The pcr amplification primer base sequence of described MYH7 gene extron as: shown in the SEQ ID NO:3-28;
The pcr amplification primer base sequence of described MYBPC3 gene extron as: shown in the SEQ ID NO:29-50;
The pcr amplification primer base sequence of described TNNT2 gene extron as: shown in the SEQ ID NO:51-58.
Preferably, described hypertrophic cardiomyopathy gene PCR detection kit also comprises the universal sequencing primer thing of the dna sequencing of described MYH7, MYBPC3 and each gene extron pcr amplification product of TNNT2, and described universal sequencing primer thing sequence is shown in SEQ ID NO:1-2.
Beneficial effect of the present invention is (1) auxiliary early diagnosis: find out among the family member asymptomatic hereditary affected individual and do not have hereditary affected individual; (2) the auxiliary selectivity that instructs is given birth to, and stops this disease and " spreads " in this family.
Embodiment
Hypertrophic cardiomyopathy MYH7 of the present invention, MYBPC3, TNNT2 transgenation are meant that single base that MYH7, MYBPC3, each exon of TNNT2 gene are taken place is replaced, insertion sudden change, deletion mutantion and complex mutation etc.
The present invention also provides a kind of universal sequencing primer thing of dna sequencing of the present invention, has simplified operation steps greatly.Described universal sequencing primer thing sequence is: UF:5 '-ggaggactgctcacgaact-3 '; UR:5 '-gggacacgcagtcgacatc-3 ', UF represent not methylation-specific upstream primer, and UR represents not methylation-specific downstream primer.
Hypertrophic cardiomyopathy MYH7 of the present invention, MYBPC3, TNNT2 detection method of gene mutation comprise the following steps:
(1) application or material
A. social crowd's blood; The body tissue cell; Wax stone and formalin-fixed tissue; All kinds of frozen, the fixing cells that keep.
B. blood and the above-mentioned materials thereof of suffering from myocardosis or the syndromic patient of similar myocardosis and the blood relationship personnel of family thereof.
C. the blood preparation of hypertrophic cardiomyopathy associated patient.
(2) sample DNA extracts
A. flesh tissue: commercialization DNA extraction test kit or autogamy reagent.
B. fix and paraffin organization: commercialization DNA extraction test kit.
C. blood preparation and liquid cell: commercialization DNA extraction test kit or autogamy reagent.
(3) pcr amplification
The pcr amplification of MYH7, MYBPC3, TNNT2 gene extron.Described pcr amplification is meant that reaction solution is 2 μ M primers, the 2mM dNTP mix of 1 μ L, the 15mM MgCl of 1 μ L of 10 * PCR Buffer, the 1 μ L of 1 μ L
2, 1U Taq enzyme, 20ng/ μ L dna profiling add 1 μ L, adds ddH then
2O to 10 μ L.Reaction conditions is: 94 ℃ of pre-sex change 5 minutes; 94 ℃ of sex change 30 seconds, 65 ℃ of annealing 30 seconds, 72 ℃ were extended totally 35 circulations 2 minutes; 72 ℃ were extended 5 minutes.
(4) dna sequencing and interpretation of result.
PCR reaction system in the described sequencing reaction comprises sequencing primer, PCR purified product and dideoxy chain termination dna sequencing.The reaction system of described dideoxy chain termination dna sequencing is primer, the 1.875uL sterilization deionized water of 2.5 * BigDye, 0.875uL5 * BigDye Seq Buffer, the 1uL5pmoL/ μ L of 0.25uL, the PCR product of 1uL purifying;
Reaction conditions: 94 ℃ of pre-sex change 2 minutes; 94 ℃ of sex change 10 seconds, 55 ℃ of annealing 10 seconds, 60 ℃ were extended 25 circulations 3 minutes.
Embodiment 1
A kind of hypertrophic cardiomyopathy gene PCR detection kit provided by the invention, comprise the primer base sequence of pcr amplification order-checking of the gene extron of MYH7, MYBPC3 and TNNT2, also comprise pcr amplification reaction liquid: the 2 μ M primers of 10 * PCR Buffer of 1 μ L, 1 μ L, the 2mM dNTP mix of 1 μ L, the MgCl of 1 μ L 15mM
2, 1U Taq enzyme, 1 μ L 20ng/ μ L dna profiling, add ddH
2O supplies volume to 10 μ L.
The PCR primer sequence of described MYH7 gene extron sees Table 1, classifies the GenBank database login as with reference to genome sequence and number is the sequence of NM_000364.1 (reference sequences of this patent is revised to some extent to this).
The PCR primer sequence of described MYBPC3 gene extron sees Table 2, classifies the GenBank database login as with reference to genome sequence and number is the sequence of U91629.1.
The PCR primer sequence of described TNNT2 gene extron sees Table 3, classifies the GenBank database login as with reference to genome sequence and number is the sequence of NM_000364.1 (reference sequences of this patent is revised to some extent to this).
Table 1 MYH7 gene extron PCR primer sequence
Table 2 MYBPC3 gene extron PCR primer sequence
Table 3 TNNT2 gene extron PCR primer sequence
Embodiment 2
1.PCR-sequencing detects the sudden change of MYH7 gene extron
Research object is the clear and definite hypertrophic cardiomyopathy patient of hospital diagnosis, and totally 80 examples are through the family investigation consanguinity-less relation.Wherein, comprise hypertrophic cardiomyopathy family propositus 40 people, relevant 285 people of family member, Sporadic cases 40 people.Normal research contrast 80 examples are the healthy people of sex, age-matched.
Get patient EDTA anti-freezing venous blood 3mL, manage packing, every pipe 300 μ L with 1.5mL.Every pipe adds 500 μ L erythrocyte cracked liquid (10mM PH=7.5 Tris-Cl, 0.32M sucrose, 1%Triton-X-100,5mM MgCl
2), the centrifugal 30s of 9000rpm outwells supernatant behind the mixing.Repeat above step 2-3 time, till the supernatant change is limpid.In above-mentioned white corpuscle precipitation, add 300 μ L write cell lysis buffer (10mM PH=8.0 Tris-Cl, 400mM NaCl, the Na of 2mM pH8.0
2EDTA), and 40 μ L 10%SDS, concussion 30s, the suspension white corpuscle places 56 ℃ of water-bath 30min.Add 120 μ L 5M NaCl then, the centrifugal 3min of 12000rpm behind the mixing.Then supernatant is transferred in the clean 1.5mL test tube of another, added the dehydrated alcohol of 2 times of volumes (about 900 μ L) then, the centrifugal 5min of 12000rpm behind the mixing.Abandon supernatant then, add 500 μ L, 70% ethanol, light shaking several seconds, the centrifugal 3min of 12000rpm.Abandon supernatant, add 500 μ L, 70% ethanol once more, light shaking several seconds, the centrifugal 3min of 12000rpm.Abandon supernatant, air-dry, add ddH
2O 40-50 μ L measures OD
260/280(the OD value is proper at 1.7-1.9) ,-20 ℃ of preservations are standby.
The pcr amplification of a.MYH7 gene extron
Used pcr amplification primer sees Table 1, and pcr amplification is meant that reaction solution is 2 μ M primers, the 2mM dNTP mix of 1 μ L, the 15mM MgCl of 1 μ L of 10 * PCR Buffer, the 1 μ L of 1 μ L
2, 1U Taq enzyme, 20ng/ μ L dna profiling add 1 μ L, adds ddH then
2O to 10 μ L.
Reaction conditions is: 94 ℃ of pre-sex change 5 minutes; 94 ℃ of sex change 30 seconds, 65 ℃ of annealing 30 seconds, 72 ℃ were extended totally 35 circulations 2 minutes; 72 ℃ were extended 5 minutes.
According to above-mentioned condition the genomic dna of each patient or contrast is carried out pcr amplification.
B. the purifying of amplified production
Get 5 μ L amplified productions, to the Fast AP of Exo I that wherein adds 0.4 μ L 5U/ μ L and 1.6 μ L 1U/ μ L, after mixing was centrifugal, in 37 ℃ of following 15min, 85 ℃ of following 15min carried out enzyme and cut purifying.Every then pipe adds 15 μ L ddH
2O carries out diluted for use.
The sequencing reaction of c.PCR product
PCR reaction system in the sequencing reaction comprises sequencing primer, PCR purified product and dideoxy chain termination dna sequencing.
(every pipe adds 1 μ L 125mM EDTA to adopt classical EDTA-Ethanol Method; Every pipe adds 25 μ L, 100% alcohol, mixing, and the room temperature lucifuge is placed 15min; 4 ℃ of centrifugal 30min of 12000rpm remove alcohol at once; Every pipe adds 70-100 μ L 70% alcohol, mixing, and 4 ℃ of centrifugal 15min of 12000rpm remove alcohol at once; Allow remaining alcohol volatilization do) purifying order-checking PCR product, the product that purifying is good adds 10 μ L Hi-Di methane amides, behind the vibration mixing, checks order with the ABI3730xl sequenator, and the universal sequencing primer thing is for being: UF:5 '-ggaggactgctcacgaact-3 '; UR:5 '-gggacacgcagtcgacatc-3 ', UF represent not methylation-specific upstream primer; UR represents not methylation-specific downstream primer, and the data after the order-checking are carried out data analysis with Sequence Analysis5.2 and SeqScape 2.6 softwares, compare with reference sequences, and the mutant nucleotide sequence that filters out is thus listed in the table 4.
The reaction system of described dideoxy chain termination dna sequencing is primer, the 1.875uL sterilization deionized water of 2.5 * BigDye, 0.875uL5 * BigDye Seq Buffer, the 1uL5pmoL/ μ L of 0.25uL, the PCR product of 1uL purifying;
Reaction conditions: 94 ℃ of pre-sex change 2 minutes; 94 ℃ of sex change 10 seconds, 55 ℃ of annealing 10 seconds, 60 ℃ were extended 25 circulations 3 minutes.
Table 4 80 routine hypertrophic cardiomyopathy patient MYH7 gene mutation for screening results
2, the PCR-sequencing detects the sudden change of MYBPC3 gene extron
The pcr amplification of MYBPC3 gene extron is similar substantially to 2, and just primer changes the primer in the table 2 into.The purifying of the purifying of amplified production and sequencing reaction and order-checking product carries out according to embodiment 2 operations.The mutant nucleotide sequence that filters out is thus listed in the table 5.
Table 5 80 routine hypertrophic cardiomyopathy patient MYBPC3 gene mutation for screening results
3, the PCR-sequencing detects the sudden change of TNNT2 gene extron
The pcr amplification of TNNT2 gene extron is similar substantially to embodiment 2, and just primer changes the primer in the table 3 into.The purifying of the purifying of amplified production and sequencing reaction and order-checking product carries out according to embodiment 2 operations.The mutant nucleotide sequence that filters out is thus listed in the table 6.
The routine hypertrophic cardiomyopathy patient TNNT2 of table 680 gene mutation for screening result
In 80 routine patients, find no the sudden change that can cause dilated cardiomyopathy.Do not find that in 80 routine normal control samples above-mentioned site mutation and other can cause the sudden change of HCM.
The present invention helps: (1) early diagnosis: find out among the family member asymptomatic hereditary affected individual and do not have hereditary affected individual; (2) instruct the selectivity fertility, stop this disease and in this family, " spread "; (3) hypertension-myocardial hypertrophy is merged the hypertrophic cardiomyopathy patient and carry out differential diagnosis; (4) carry out differential diagnosis to sportsmen's cardiac muscle is plump with hypertrophic cardiomyopathy; (5) distinguish with the myocardosis of other types (as dilated cardiomyopathy etc.), certain booster action is played in treatment.
The above only is embodiments of the invention; be not so limit claim of the present invention; everyly utilize specification sheets of the present invention and equivalent structure of being done or equivalent flow process conversion; or directly or indirectly be used in other relevant technical fields, all in like manner be included in the scope of patent protection of the present invention.
Claims (9)
1. a hypertrophic cardiomyopathy methods of genotyping is characterized in that, described method comprises:
A, gene M YH7, MYBPC3 and TNNT2 in the sample DNA are carried out the detection of transgenation, the detection of described transgenation comprises the pcr amplification and the dna sequencing of the gene extron of MYH7, MYBPC3 and TNNT2,
B, the sequence that obtains after the amplification order-checking among the step b is compared with the standard sequence in the database, thus definite gene type result.
2. by the described hypertrophic cardiomyopathy methods of genotyping of claim 1, it is characterized in that described pcr amplification and dna sequencing comprise PCR sequence amplification, PCR product purification and dideoxy chain termination dna sequencing.
3. by the described hypertrophic cardiomyopathy methods of genotyping of claim 2, it is characterized in that the reaction system of described PCR sequence amplification is 2 μ M primers, the 2mM dNTP mix of 1 μ L, the MgCl of 1 μ L15mM of 10 * PCR Buffer, the 1 μ L of 1 μ L
2, the Taq enzyme of 1U, the dna profiling of 1 μ L 20ng/ μ L, add distilled water to 10 μ L then,
Reaction conditions is: 94 ℃ of pre-sex change 5 minutes; 94 ℃ of sex change 30 seconds, 65 ℃ of annealing 30 seconds, 72 ℃ were extended totally 35 circulations 2 minutes; 72 ℃ were extended 5 minutes.
4. by the described hypertrophic cardiomyopathy methods of genotyping of claim 2, it is characterized in that the reaction system of described dideoxy chain termination dna sequencing is primer, the 1.875uL sterilization deionized water of 2.5 * BigDye, 0.875uL5 * BigDye Seq Buffer, the 1uL5pmoL/ μ L of 0.25uL, the PCR product of 1uL purifying;
Reaction conditions: 94 ℃ of pre-sex change 2 minutes; 94 ℃ of sex change 10 seconds, 55 ℃ of annealing 10 seconds, 60 ℃ were extended 25 circulations 3 minutes.
5. by the described hypertrophic cardiomyopathy methods of genotyping of claim 2, it is characterized in that described PCR product purification adopts the EDTA-Ethanol Method.
6. by each described hypertrophic cardiomyopathy methods of genotyping of claim 1-5, it is characterized in that the used universal sequencing primer thing sequence of described dideoxy chain termination dna sequencing is shown in SEQ ID NO:1-2.
7. by the described hypertrophic cardiomyopathy methods of genotyping of claim 1, it is characterized in that, the pcr amplification primer base sequence of described MYH7 gene extron as: shown in the SEQ ID NO:3-28;
The pcr amplification primer base sequence of described MYBPC 3 gene extrons as: shown in the SEQ ID NO:29-50;
The pcr amplification primer base sequence of described TNNT2 gene extron as: shown in the SEQ ID NO:51-58.
8. a hypertrophic cardiomyopathy gene PCR detection kit is characterized in that, comprises the pcr amplification primer of the gene extron of MYH7, MYBPC3 and TNNT2,
The pcr amplification primer base sequence of described MYH7 gene extron as: shown in the SEQ ID NO:3-28;
The pcr amplification primer base sequence of described MYBPC3 gene extron as: shown in the SEQ ID NO:29-50;
The pcr amplification primer base sequence of described TNNT2 gene extron as: shown in the SEQ ID NO:51-58.
9. by the described hypertrophic cardiomyopathy gene PCR of claim 8 detection kit, it is characterized in that, the universal sequencing primer thing that also comprises the dna sequencing of each gene extron pcr amplification product of described MYH7, MYBPC3 and TNNT2, described universal sequencing primer thing sequence is shown in SEQ ID NO:1-2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110192745 CN102242212B (en) | 2011-07-08 | 2011-07-08 | HCM (Hypertrophic Cardiomyopathy) genotyping method and kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110192745 CN102242212B (en) | 2011-07-08 | 2011-07-08 | HCM (Hypertrophic Cardiomyopathy) genotyping method and kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102242212A true CN102242212A (en) | 2011-11-16 |
| CN102242212B CN102242212B (en) | 2013-04-10 |
Family
ID=44960455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110192745 Active CN102242212B (en) | 2011-07-08 | 2011-07-08 | HCM (Hypertrophic Cardiomyopathy) genotyping method and kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102242212B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106811518A (en) * | 2016-08-17 | 2017-06-09 | 上海易瑞生物科技有限公司 | A kind of thyroid cancer tumor susceptibility gene detection and genotyping kit and its application |
| CN107287317A (en) * | 2017-07-10 | 2017-10-24 | 中国人民解放军第四军医大学 | MYH7 A934V mutators are used for the application for preparing Diagnosis of Hypertrophic Cardiomyopathy kit |
| CN108611398A (en) * | 2012-01-13 | 2018-10-02 | Data生物有限公司 | Genotyping is carried out by new-generation sequencing |
| CN108642155A (en) * | 2018-06-15 | 2018-10-12 | 合肥艾迪康临床检验所有限公司 | Detect method, oligonucleotides and its application of MYH7 gene mutations |
| CN109750099A (en) * | 2019-01-30 | 2019-05-14 | 中国人民解放军总医院 | It is a kind of for detecting/the probe groups of tumor susceptibility gene of causing a disease of sudden cardiac death |
| CN110684838A (en) * | 2019-11-08 | 2020-01-14 | 百世诺（北京）医疗科技有限公司 | Kit for detecting gene of hypertrophic cardiomyopathy |
| CN111675759A (en) * | 2020-07-15 | 2020-09-18 | 中南大学 | Hypertrophic cardiomyopathy pathogenic gene and application thereof |
| CN112941175A (en) * | 2021-04-14 | 2021-06-11 | 大理大学 | Primer probe composition for detecting MYH7 gene mutation and application thereof |
| CN115851751A (en) * | 2022-12-21 | 2023-03-28 | 百世诺（北京）医疗科技有限公司 | Hypertrophic cardiomyopathy variant gene TNNT2 and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070207473A1 (en) * | 2005-11-01 | 2007-09-06 | Mayo Foundation For Medical Education And Research | Hypertrophic cardiomyopathy |
| CN101134961A (en) * | 2007-08-02 | 2008-03-05 | 中国人民解放军第二军医大学 | Hypertrophic type cardiomyopathy PRKAG2 gene mutation and detecting method thereof |
| ES2340459A1 (en) * | 2004-06-07 | 2010-06-02 | Universidade Da Coruña Y En Su Nombre Y Representacion, El Rector, D. Jose Maria Barja Perez | Method to diagnose or determine the genetic predisposition to develop hypertrophic myocardiathy (Machine-translation by Google Translate, not legally binding) |
-
2011
- 2011-07-08 CN CN 201110192745 patent/CN102242212B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2340459A1 (en) * | 2004-06-07 | 2010-06-02 | Universidade Da Coruña Y En Su Nombre Y Representacion, El Rector, D. Jose Maria Barja Perez | Method to diagnose or determine the genetic predisposition to develop hypertrophic myocardiathy (Machine-translation by Google Translate, not legally binding) |
| US20070207473A1 (en) * | 2005-11-01 | 2007-09-06 | Mayo Foundation For Medical Education And Research | Hypertrophic cardiomyopathy |
| CN101134961A (en) * | 2007-08-02 | 2008-03-05 | 中国人民解放军第二军医大学 | Hypertrophic type cardiomyopathy PRKAG2 gene mutation and detecting method thereof |
Non-Patent Citations (3)
| Title |
|---|
| MÓNICA GARCÍA-CASTRO等: "Mutations in Sarcomeric Genes MYH7, MYBPC3，TNNT2, TNNI3, and TPM1 in Patients With Hypertrophic Cardiomyopathy", 《REV ESP CARDIOL》, vol. 62, no. 1, 31 December 2009 (2009-12-31), pages 48 - 56, XP026302463, DOI: doi:10.1016/S1885-5857(09)71513-0 * |
| 刘文玲等: "十个汉族家族性肥厚型心肌病MYH7、MYBPC3和TNNT2基因筛查结果及相应的临床特征", 《中华心血管病杂志》, vol. 34, no. 3, 31 March 2006 (2006-03-31), pages 203 * |
| 王虎等: "心脏肌球蛋白重链基因c.1273G>A 突变与肥厚型心肌病的关联分析", 《遗传》, vol. 31, no. 5, 31 May 2009 (2009-05-31) * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108611398A (en) * | 2012-01-13 | 2018-10-02 | Data生物有限公司 | Genotyping is carried out by new-generation sequencing |
| CN106811518A (en) * | 2016-08-17 | 2017-06-09 | 上海易瑞生物科技有限公司 | A kind of thyroid cancer tumor susceptibility gene detection and genotyping kit and its application |
| CN107287317A (en) * | 2017-07-10 | 2017-10-24 | 中国人民解放军第四军医大学 | MYH7 A934V mutators are used for the application for preparing Diagnosis of Hypertrophic Cardiomyopathy kit |
| CN108642155A (en) * | 2018-06-15 | 2018-10-12 | 合肥艾迪康临床检验所有限公司 | Detect method, oligonucleotides and its application of MYH7 gene mutations |
| CN109750099A (en) * | 2019-01-30 | 2019-05-14 | 中国人民解放军总医院 | It is a kind of for detecting/the probe groups of tumor susceptibility gene of causing a disease of sudden cardiac death |
| CN110684838A (en) * | 2019-11-08 | 2020-01-14 | 百世诺（北京）医疗科技有限公司 | Kit for detecting gene of hypertrophic cardiomyopathy |
| CN111675759A (en) * | 2020-07-15 | 2020-09-18 | 中南大学 | Hypertrophic cardiomyopathy pathogenic gene and application thereof |
| CN111675759B (en) * | 2020-07-15 | 2021-08-06 | 中南大学 | Hypertrophic cardiomyopathy pathogenic gene and application thereof |
| CN112941175A (en) * | 2021-04-14 | 2021-06-11 | 大理大学 | Primer probe composition for detecting MYH7 gene mutation and application thereof |
| CN112941175B (en) * | 2021-04-14 | 2022-06-17 | 大理大学 | Primer probe composition for detecting MYH7 gene mutation and application thereof |
| CN115851751A (en) * | 2022-12-21 | 2023-03-28 | 百世诺（北京）医疗科技有限公司 | Hypertrophic cardiomyopathy variant gene TNNT2 and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102242212B (en) | 2013-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102242212B (en) | HCM (Hypertrophic Cardiomyopathy) genotyping method and kit | |
| Palmer et al. | Gene expression differences in mice divergently selected for methamphetamine sensitivity | |
| CN101928776A (en) | PCR-SBT method for HLA genotyping and reagent thereof | |
| CN103571847B (en) | FOXC1 gene mutation bodies and its application | |
| WO2018119421A1 (en) | Compositions and methods of using rna fragments | |
| CN106755399B (en) | A kind of I type neurofibromatosis pathogenic mutation gene and the Etiologic reagent based on this mutated gene | |
| CN109735610B (en) | Gene polymorphism site for detecting Bombay-like blood type | |
| CN101287846A (en) | Method for the diagnosing thromboembolia disorders and coronary heart diseases | |
| AU2016351311B9 (en) | SCAP gene mutant and the application thereof | |
| CN104630374A (en) | Rheumatoid-arthritis-related single-gene single nucleotide polymorphism site and application thereof | |
| CN106834287A (en) | A kind of SNP marker for detecting RhD negative phenotypes | |
| CN101200758A (en) | Method for detecting COL7A1 gene mutation and uses thereof | |
| CN1763196B (en) | Gene mutation type and gene sequencing method | |
| CN111621563A (en) | Primer group for detecting human SERPINF1 gene mutation and kit thereof | |
| CN109457031B (en) | BRCA2 gene g.32338309A & gtG mutant and application thereof in breast cancer auxiliary diagnosis | |
| CN109355379B (en) | Kit for detecting autosomal dominant hereditary deafness family-induced deafness gene mutation | |
| CN104894261B (en) | Kit for predicting curative effect of ranibizumab on treatment of age-related macular degeneration | |
| JP4119490B2 (en) | Genetic diagnosis of diseases involving TNF-α promoter | |
| CN100519748C (en) | Human genetic deaf related GJB6 mutant gene and its uses in gennetic deaf diagnosis | |
| CN107312775B (en) | Application of hsa _ circRNA _103096 in diagnosis, treatment and prognosis of liver cancer | |
| CN107029238B (en) | Applications of the LINC01094 in diagnosis and treatment cerebral arterial thrombosis | |
| CN110484623A (en) | A kind of RB1 mutated gene, primer, detection method, kit and application | |
| CN101134961A (en) | Hypertrophic type cardiomyopathy PRKAG2 gene mutation and detecting method thereof | |
| CN110055258A (en) | A kind of site breast cancer related gene ERBB2 g.39717320G > A mutant and its application | |
| CN114381513B (en) | Biomarker related to X-linked lymphoproliferative disorder and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A genotyping method and detection kit for hypertrophic cardiomyopathy Effective date of registration: 20220112 Granted publication date: 20130410 Pledgee: Yao Qingfeng Pledgor: TRIPLEX INTERNATIONAL BIOSCIENCES (CHINA) Co.,Ltd. Registration number: Y2022350000005 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |